Kyntra Bio (KYNB) stock
Breakaway doesn't score KYNB. It is too small and too thinly traded for a fair Quality Score.
Follow KYNB's trial news. Pro members can get an alert when Kyntra Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. 3,243 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live. So can you, free, with no account.
What's next for KYNB, and how long its cash lasts
From Kyntra Bio’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into the fourth quarter of 2027 (8-K, Aug 31).
Dilution on the horizon
No shelf registration of its own or at-the-market program on file in the last three years.
Insiders
CEO Thane Wettig bought 2,800 shares on May 14.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 27 daysINOInovio Pharmaceuticals
INOINO-3107
- In 38 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 50 daysCAPRCapricor Therapeutics
CAPRDrug not named
KYNB's latest filings
- Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
- 2 insider filings
- Quarterly report
Why KYNB isn't scored
The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares a day. KYNB is worth about $25.5M and trades about 26,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.